Zymeworks Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ZYME Nasdaq 2836 www.zymeworks.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences - Nov 21st, 2024 11:05 am
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) - Nov 21st, 2024 11:00 am
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors - Nov 5th, 2024 11:00 am
Zymeworks Third Quarter 2024 Earnings: Revenues Disappoint - Nov 2nd, 2024 1:53 pm
Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year - Nov 1st, 2024 12:54 pm
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results - Oct 31st, 2024 8:05 pm
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference - Oct 25th, 2024 10:00 am
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers - Oct 21st, 2024 10:00 am
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024 - Oct 10th, 2024 10:30 am
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference - Sep 18th, 2024 10:00 am
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c) - Sep 3rd, 2024 8:30 pm
News Flash: Analysts Just Made A Captivating Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Forecasts - Aug 7th, 2024 12:13 pm
Zymeworks Inc. (NASDAQ:ZYME) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year - Aug 4th, 2024 1:44 pm
Zymeworks Second Quarter 2024 Earnings: Misses Expectations - Aug 3rd, 2024 1:42 pm
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock - Aug 1st, 2024 8:10 pm
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results - Aug 1st, 2024 8:05 pm
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer - Jul 25th, 2024 8:30 pm
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate - Jul 22nd, 2024 10:00 am
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024 - Jul 11th, 2024 10:30 am
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers - Jun 17th, 2024 10:00 am